 | |
| Industry | Pharmaceutical; Psychedelic medicine |
|---|---|
| Founded | 2020 in Denver, Colorado |
| Headquarters | , |
| Website | mydecine.com |
Mydecine Innovations Group, or simply Mydecine, is an American and Canadian pharmaceutical company that is developing psychedelics and entactogens as medicines. [2] [3] [4]
Contents
In August 2022, it was reported that Mydecine was experiencing financial difficulties and might cease operations. [4] [5] However, the company was able to obtain more funding and did not shutdown. [4] Mydecine made the first legal import of magic mushrooms into Canada in 2021. [6] [7]
Mydecine's drug candidates include the psychedelics psilocybin (MYCO-001, MYCO-003), [8] [9] [10] MYCO-004 (a patch-delivered tryptamine), [11] [12] and MYCO-005 (a novel aza psilocin analogue with putatively better safety) [13] [14] [2] and the novel MDMA-like entactogens MYCO-002 (putatively safer), [15] [16] MYCO-006 (short-acting), [17] [18] [5] [3] and MYCO-007 (short-acting). [19] [20] [21] [1]
Although the chemical structures of most of its drug candidates have not been disclosed, Mydecine has patented 5-BZT-MDMA (MY100) and 6-BZT-MDMA (MY101) as short-acting MDMA analogues. [22] [23] [24]
